A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen

Gynecological Endocrinology

Volumn 21, Issue 2, 2005, Pages 101-105

  Vashisht, Arvind ^a,c   Wadsworth, Fred ^a   Carey, Adam ^a   Carey, Beverley ^a   Studd, John ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Climacteric symptoms; Plasma hormone levels; Transdermal natural progesterone

Indexed keywords

ESTRADIOL; PROGESTELLE; PROGESTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; LUTEAL PHASE; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL;

ADMINISTRATION, CUTANEOUS; ANXIETY; DEPRESSION; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; LIBIDO; MIDDLE AGED; OINTMENTS; POSTMENOPAUSE; PROGESTERONE;

EID: 25144523058     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500128583     Document Type: Article

References (30)

1. Magos AL, Brewster E, Singh R, O'Dowd T, Brincat M, Studd JW. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 1986;93:1290-1296.
2. Nahoul K, Dehennin L, Jondet M, Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas 1993;16:185-202.
3. Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. Fertil Steril 1985;44:622-626.
4. Padwick ML, Endacott J, Matson C, Whitehead MI. Absorption and metabolism of oral progesterone when administered twice daily. Fertil Steril 1986;46:402-407.
5. Arafat ES, Hargrove JT, Maxson WS, Desiderio DM, Wentz AC, Andersen RN. Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. Am J Obstet Gynecol 1988;159:1203-1209.
6. Norman TR, Morse CA, Dennerstein L. Comparative bioavailability of orally and vaginally administered progesterone. Fertil Steril 1991;56:1034-1039.
7. Fanchin R, De Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R. Transvaginal administration of progesterone. Obstet Gynecol 1997;90:396-401.
8. Wren BG, Day RO, McLachlan AJ, Williams KM. Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women. Climacteric 2003;6:104-111.
9. Simon JA. Micronized progesterone: vaginal and oral uses. Clin Obstet Gynecol 1995;38:902-914.
10. Sitruk-Ware R, de Lignieres B, Basdevant A, Mauvais-Jarvis P. Absorption of percutaneous oestradiol in postmenopausal women. Maturitas 1980;2:207-211.
11. Waddell BJ, O'Leary PC. Distribution and metabolism of topically applied progesterone in a rat model. J Steroid Biochem Mol Biol 2002;80:449-455.
12. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225-228.
13. Lee JR. Osteoporosis reversal with transdermal progesterone. Lancet 1990;336:1327.
14. Ferre F, Uzan M, Janssens Y, Tanguy G, Jolivet A, Breuiller M, Sureau C, Cedard L. Oral administration of micronized natural progesterone in late human pregnancy. Effects on progesterone and estrogen concentrations in the plasma, placenta, and myometrium. Am J Obstet Gynecol 1984;148:26-34.
15. Bourgain C, Devroey P, Van Waesberghe L, Smitz J, Van Steirteghem AC. Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod 1990;5:537-543.
16. Bulletti C, De Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, Franceschetti F. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod 1997;12:1073-1079.
17. Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol 1999;180:1504-1511.
18. Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003;10:13-18.
19. Cooper A, Spencer C, Whitehead MI, Ross D, Barnard GJ, Collins WP. Systemic absorption of progesterone from Progest® cream in postmenopausal women. Lancet 1998; 351:1255-1256.
20. Wren BG, McFarland K, Edwards L. Micronised transdermal progesterone and endometrial response. Lancet 1999;354:1447-1448.
21. Bolaji II, Tallon DF, O'Dwyer E, Fottrell PF. Assessment of bioavailability of oral micronized progesterone using a salivary progesterone enzymeimmunoassay. Gynecol Endocrinol 1993;7:101-110.
22. Mircioiu C, Perju A, Neagu A, Gnu E, Calin G, Miron DS. Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. Eur J Drug Metab Pharmacokinet 1998;23:391-396.
23. Johnson ME, Blankschtein D, Langer R. Permeation of steroids through human skin. J Pharm Sci 1995;84:1144-1146.
24. Lee JR. Use of Pro-Gest cream in postmenopausal women. Lancet 1998;352:905.
25. Lewis JG, McGill H, Patton VM, Elder PA. Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas 2002;41:1-6.
26. Darj E, Nilsson S, Axelsson O, Hellberg D. Clinical and endometrial effects of oestradiol and progesterone in post-menopausal women. Maturitas 1991;13:109-115.
27. Bolaji II, Mortimer G, Grimes H, Talion DF, O'Dwyer E, Fottrell PF. Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women. Gynecol Endocrinol 1996;10:41-47.
28. Warren MP, Biller BM, Shangold MM. A new clinical option for hormone replacement therapy in women with secondary amenorrhea: effects of cyclic administration of progesterone from the sustained-release vaginal gel Crinone (4% and 8%) on endometrial morphologic features and withdrawal bleeding. Am J Obstet Gynecol 1999;180:42-48.
29. Maruo T, Mishell DR, Ben Chetrit A, Hochner-Celnikier D, Hamada AL, Nash HA. Vaginal rings delivering progesterone and estradiol may be a new method of hormone replacement therapy. Fertil Steril 2002;78:1010-1016.
30. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-333.